Top Page
Plus Therapeutics
(NASDAQ:PSTV)
Plus Therapeutics (PSTV) vs. SPDR S&P 500 ETF (SPY)
Plus Therapeutics Business Overview & Revenue Model
Plus Therapeutics Earnings Call Summary
Plus Therapeutics Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.82M | 4.91M | 224.00K | 0.00 | 303.00K |
| Gross Profit | 4.97M | -4.78M | -488.00K | -66.00K | -2.40M |
| EBITDA | -8.40M | -12.69M | -18.85M | -12.05M | -6.76M |
| Net Income | -12.98M | -13.32M | -20.27M | -13.40M | -8.24M |
Balance Sheet | |||||
| Total Assets | 6.63M | 11.39M | 23.87M | 21.98M | 12.11M |
| Cash, Cash Equivalents and Short-Term Investments | 3.61M | 8.55M | 18.12M | 18.40M | 8.35M |
| Total Debt | 3.37M | 4.18M | 5.64M | 6.99M | 7.00M |
| Total Liabilities | 15.58M | 12.74M | 17.42M | 11.14M | 9.07M |
| Stockholders Equity | -8.95M | -1.35M | 6.45M | 10.84M | 3.03M |
Cash Flow | |||||
| Free Cash Flow | -11.24M | -13.01M | -13.48M | -10.42M | -8.93M |
| Operating Cash Flow | -10.55M | -12.85M | -12.97M | -10.28M | -8.43M |
| Investing Cash Flow | -4.11M | -160.00K | -759.00K | -82.00K | -493.00K |
| Financing Cash Flow | 6.19M | 3.44M | 13.45M | 20.42M | -319.00K |
Plus Therapeutics Technical Analysis
Plus Therapeutics Risk Analysis
Plus Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $13.62M | 0.78 | -162.42% | ― | -82.24% | ― | |
52 Neutral | $7.39B | >-0.01 | -63.86% | 2.36% | 16.15% | 0.36% | |
40 Underperform | $19.18M | ― | 249.03% | ― | -14.43% | 16.04% | |
| ― | $14.13M | ― | -2264.31% | ― | ― | ― | |
42 Neutral | $593.87K | ― | ― | -95.23% | -325.89% | ||
34 Underperform | $12.68M | 2.55 | >-0.01% | ― | ― | ― | |
34 Underperform | $17.36M | ― | -616.17% | ― | ― | 71.39% |
Plus Therapeutics Corporate Events
Plus Therapeutics has entered into a Purchase Agreement with Lincoln Park, which is an accredited investor, to issue and sell securities under exemptions from the registration requirements of the Securities Act. This strategic move allows Plus Therapeutics to raise capital while leveraging regulatory exemptions, potentially impacting its financial strategy and stakeholder interests.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
On March 4, 2025, Plus Therapeutics, Inc. entered into a Securities Purchase Agreement with various purchasers, resulting in a private placement involving shares and warrants of the company’s common stock. On June 17, 2025, the company and the purchasers agreed to a letter agreement to minimize the dilutive impact of the private placement. This included the cancellation of Series A Warrants, amendment of Series B Warrants, waiver of the Registration Rights Agreement, and the return of certain shares and warrants by the purchasers. These actions are aimed at reducing the potential negative impact on the company’s stockholders’ equity and facilitating future capital raising efforts.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
On June 3, 2025, Plus Therapeutics, Inc. received a letter from Nasdaq stating that the company had regained compliance with Rule 5250(c)(1) after filing its Quarterly Report for the period ended March 31, 2025. However, the company was notified of non-compliance with the Minimum Stockholders’ Equity Requirement, leading to a decision to delist its securities unless an appeal is made. Plus Therapeutics plans to request a hearing to appeal this decision, during which its stock will continue trading on the Nasdaq Capital Market.
The most recent analyst rating on (PSTV) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
On May 21, 2025, Plus Therapeutics received a notice from Nasdaq due to a delay in filing its Quarterly Report for the period ending March 31, 2025, which resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until July 21, 2025, to submit a compliance plan, with a possible extension until November 17, 2025, if accepted. This notification does not immediately affect the company’s Nasdaq listing, and Plus Therapeutics is working to file the report promptly to regain compliance.
The most recent analyst rating on (PSTV) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
On May 16, 2025, Plus Therapeutics, Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days. This situation does not immediately affect the company’s stock listing or trading, but Plus Therapeutics has until November 12, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. If compliance is not achieved by this date, the company may qualify for an additional 180-day period to meet the requirement, potentially through measures like a reverse stock split. Failure to comply could result in delisting, although the company can appeal such a decision.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
On April 18, 2025, Plus Therapeutics, Inc. appointed Mr. Kyle Guse to its Board of Directors, filling the vacancy left by Mr. Greg Petersen’s resignation. Mr. Guse, who has extensive experience in finance, corporate governance, and law, will also serve on the Audit and Compensation Committees, and as Chairman of the Audit Committee. His appointment is seen as a strategic move to strengthen the company’s governance and financial oversight.